The tumor suppressor gene RhoBTB1 is a novel target of miR-31 in human colon cancer

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 676-682

  Xu, Rui Si ^a   Wu, Xiao Dong ^a   Zhang, Si Qi ^a   Li, Chang Feng ^a   Yang, Lei ^a   Li, Dan Dan ^a   Zhang, Bao Gang ^a   Zhang, Ying ^a   Jin, Jing Peng ^a   Zhang, Bin ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Colon cancer; MiR 31; RhoBTB1; Tumorigenesis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AGAROSE; MICRORNA 31; RHO FACTOR; RHOBTB1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; COLON CANCER; COLON CARCINOGENESIS; COLONY FORMATION; CONTROLLED STUDY; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE;

CARCINOGENESIS; CELL PROLIFERATION; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GTP-BINDING PROTEINS; HT29 CELLS; HUMANS; MICRORNAS; STEM CELLS; TUMOR SUPPRESSOR PROTEINS;

EID: 84873679836     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1746     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Colorectal Cancer Survival by Stage: National Cancer Intelligence Network, 2009.
3. Figer A, Perez-Staub N, Carola E, et al: FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 110: 2666-2671, 2007.
4. Becker H: Surgery of colorectal carcinoma. Praxis 84: 1371-1372, 1995.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
6. Tsai HL, Yeh YS, Yu FJ, Lu CY, Chen CF, Chen CW, Chang YT and Wang JY: Predicting factors of postoperative relapse in T2-4N0M0 colorectal cancer patients via harvesting a minimum of 12 lymph nodes. Int J Colorectal Dis 24: 177-183, 2009.
7. Longo WE and Johnson FE: The preoperative assessment and postoperative surveillance of patients with colon and rectal cancer. Surg Clin North Am 82: 1091-1108, 2002.
8. Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, et al: MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 33: 732-739, 2012.
9. Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105, 2009.
10. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906, 2000.
11. Chen CZ, Li L, Lodish HF and Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83-86, 2004.
12. Lai EC: Micro RNAs are complementary to 3'UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30: 363-364, 2002.
13. Engels BM and Hutvagner G: Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 25: 6163-6169, 2006.
14. Cheng AM, Byrom MW, Shelton J and Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33: 1290-1297, 2005.
15. Calin GA, Ferracin M, Cimmino A, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801, 2005.
16. Bushati N and Cohen SM: microRNA functions. Annu Rev Cell Dev Biol 23: 175-205, 2007.
17. Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med 60: 167-179, 2009.
18. Slaby O, Svoboda M, Michalek J and Vyzula R: MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 8: 102, 2009.
19. Schetter AJ and Harris CC: Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol 38: 734-742, 2011.
20. Bandres E, Cubedo E, Agirre X, et al: Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5: 29, 2006.
21. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R and Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72: 397-402, 2007.
22. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF and Wong N: MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135: 257-269, 2008.
23. Liu X, Sempere LF, Ouyang H, et al: MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 120: 1298-1309, 2010.
24. Liu X, Chen Z, Yu J, Xia J and Zhou X: MicroRNA profiling and head and neck cancer. Comp Funct Genomics, 837514, 2009.
25. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL and Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046, 2009.
26. Laurila EM, Sandström S, Rantanen LM, Autio R and Kallioniemi A: Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells. Genes Chromosomes Cancer 51: 557-568, 2012.
27. Cottonham CL, Kaneko S and Xu L: miR-21 and miR-31 con-verge on TIAM 1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 285: 35293-35302, 2010.
28. Wang CJ, Stratmann J, Zhou ZG and Sun XF: Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer 10: 616, 2010.
29. Hamaguchi M, Meth JL, von Klitzing C, et al: DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 99: 13647-13652, 2002.
30. Knowles MA, Aveyard JS, Taylor CF, Harnden P and Bass S: Mutation analysis of the 8p cand idate tumour suppressor genes DBC2 (RHOBT B2) and LZTS1 in bladder cancer. Cancer Lett 225: 121-130, 2005.
31. Cho YG, Choi BJ, Kim CJ, Song JH, Zhang C, Nam SW, Lee JY and Park WS: Genetic analysis of the DBC2 gene in gastric cancer. Acta Oncol 47: 366-371, 2008.
32. Beder LB, Gunduz M, Ouchida M, et al: Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer. J Cancer Res Clin Oncol 132: 19-27, 2006.
33. Hwang HW and Mendel JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94: 776-780, 2006.
34. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
35. Cho WC: MicroRNAs in cancer from research to therapy. Biochim Biophys Acta 1805: 209-217, 2010.
36. Cho WC: MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42: 1273-1281, 2010.
37. Liu CJ, Tsai MM, Hung PS, et al: miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 70: 1635-1644, 2010.
38. Sahai E and Marshall CJ: RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142, 2002.
39. Gómez del Pulgar T, Benitah SA, Valerón PF, Espina C and Lacal JC: Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 27: 602-613, 2005.
40. Ellenbroek SI and Collard JG: RhoGTPases: functions and association with cancer. Clin Exp Metastasis 24: 657-672, 2007.
41. Rivero F, Dislich H, Glockner G and Noegel AA: The Dictyostelium discoideum family of Rho-related proteins. Nucleic Acids Res 29: 1068-1079, 2001.